BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2.
Nat Immunol
; 23(1): 33-39, 2022 01.
Article
Dans Anglais
| MEDLINE | ID: covidwho-1545629
ABSTRACT
The first ever US Food and Drug Administration-approved messenger RNA vaccines are highly protective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1-3. However, the contribution of each dose to the generation of antibodies against SARS-CoV-2 spike (S) protein and the degree of protection against novel variants warrant further study. Here, we investigated the B cell response to the BNT162b2 vaccine by integrating B cell repertoire analysis with single-cell transcriptomics pre- and post-vaccination. The first vaccine dose elicits a recall response of IgA+ plasmablasts targeting the S subunit S2. Three weeks after the first dose, we observed an influx of minimally mutated IgG+ memory B cells that targeted the receptor binding domain on the S subunit S1 and likely developed from the naive B cell pool. This response was strongly boosted by the second dose and delivers potently neutralizing antibodies against SARS-CoV-2 and several of its variants.
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Lymphocytes B
/
Anticorps neutralisants
/
Glycoprotéine de spicule des coronavirus
/
SARS-CoV-2
/
Vaccin BNT162
/
Anticorps antiviraux
Type d'étude:
Études expérimentales
Les sujets:
Vaccins
/
Variantes
Limites du sujet:
Humains
langue:
Anglais
Revue:
Nat Immunol
Thème du journal:
Allergie et immunologie
Année:
2022
Type de document:
Article
Pays d'affiliation:
S41590-021-01088-9
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS